Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants
Brain · 2025
DOI: 10.1093/brain/awae243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Sarah H Berth und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: TRPV Cation Channels, Channelopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Deutsche Forschungsgemeinschaft, National Institutes of Health.
Abstract (Originalsprache)
Dominant mutations in the calcium-permeable ion channel TRPV4 (transient receptor potential vanilloid 4) cause diverse and largely distinct channelopathies, including inherited forms of neuromuscular disease, skeletal dysplasias and arthropathy. Pathogenic TRPV4 mutations cause gain of ion channel function and toxicity that can be rescued by small molecule TRPV4 antagonists in cellular and animal models, suggesting that TRPV4 antagonism could be therapeutic for patients. Numerous variants in TRPV4 have been detected with targeted and whole exome/genome sequencing, but for the vast majority, their pathogenicity remains unclear. Here, we used a combination of clinical information and experimental structure-function analyses to evaluate 30 TRPV4 variants across various functional protein domains. We report clinical features of seven patients with TRPV4 variants of unknown significance and provide extensive functional characterization of these and an additional 17 variants, including structural position, ion channel function, subcellular localization, expression level, cytotoxicity and protein-protein interactions. We find that gain-of-function mutations within the TRPV4 intracellular ankyrin repeat domain target charged amino acid residues important for RhoA interaction, whereas ankyrin repeat domain residues outside of the RhoA interface have normal or reduced ion channel activity. We further identify a cluster of gain-of-function variants within the intracellular intrinsically disordered region that may cause toxicity via altered interactions with membrane lipids. In contrast, assessed variants in the transmembrane domain and other regions of the intrinsically disordered region do not cause gain of function and are likely benign. Clinical features associated with gain of function and cytotoxicity include congenital onset of disease, vocal cord weakness and motor-predominant disease, whereas patients with likely benign variants often demonstrated late-onset and sensory-predominant disease. These results provide a framework for assessing additional TRPV4 variants with respect to likely pathogenicity, which will yield critical information to inform patient selection for future clinical trials for TRPV4 channelopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
- Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
- Faculty of Chemistry and Earth Sciences, Friedrich Schiller University Jena, Institute of Organic Chemistry and Macromolecular Chemistry, Jena 07743, Germany.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
ORCID-Profile: Brett A McCray
Förderung
- NINDS NIH HHS
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Institute of Neurological Disease and Stroke
- Merkin Peripheral Neuropathy and Nerve Regeneration Center
- Membrane-associated Protein Assemblies, Machineries, and Supercomplexes
- Dr. John H. Doran Neuropathy Research Initiative
Zitieren
APA
Berth, S. H., Vo, L., Kwon, D. H., Grider, T., Damayanti, Y. S., Kosmanopoulos, G., Fox, A., Lau, A. R., Carr, P., Donohue, J. K., Hoke, M., Thomas, S., Karam, C., Fay, A. J., Meltzer, E., Crawford, T. O., Gaudet, R., Shy, M. E., Hellmich, U. A., …, & McCray, B. A. (2025). Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants. Brain. https://doi.org/10.1093/brain/awae243
Vancouver
Berth SH, Vo L, Kwon DH, Grider T, Damayanti YS, Kosmanopoulos G, et al. Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants. Brain. 2025. doi:10.1093/brain/awae243
BibTeX
@article{Berth2025,
author = {Berth, Sarah H and Vo, Linh and Kwon, Do Hoon and Grider, Tiffany and Damayanti, Yasmine S and Kosmanopoulos, Gage and Fox, Andrew and Lau, Alexander R and Carr, Patrice and Donohue, Jack K and Hoke, Maya and Thomas, Simone and Karam, Chafic and Fay, Alex J and Meltzer, Ethan and Crawford, Thomas O and Gaudet, Rachelle and Shy, Michael E and Hellmich, Ute A and Lee, Seok-Yong and Sumner, Charlotte J and McCray, Brett A},
title = {Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awae243}
}
EUVIMED